IP Library Granted Patent US 8,216,582
Granted Patent B2
US 8,216,582 · App. 12/305,648 · Granted Jul 10, 2012

Polynucleotides and polypeptide sequences involved in cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,216,582
App. No.
12/305,648
Granted
Jul 10, 2012
Kind
B2
Abstract

The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.

Claims (15)

1. A method for treating ovarian cancer, the method comprising administering to a subject having ovarian cancer an antibody, or an antigen binding fragment thereof, capable of specifically binding to a polypeptide having a sequence identical to SEQ ID NO.:70.

2. The method of claim 1 , wherein the antibody, or antigen binding fragment thereof, is capable of impairing an activity of the polypeptide in ovarian cancer cells.

3. The method of claim 2 , wherein the activity is ovarian cancer tumorigenesis.

4. The method of claim 1 , wherein the ovarian cancer is of epithelial origin.

5. The method of claim 4 , wherein the ovarian cancer is malignant.

6. The method of claim 4 , wherein the ovarian cancer is classified as serous, clear cell or endometroid.

7. The method of claim 6 , wherein the ovarian cancer is malignant.

8. The method of claim 1 , wherein the ovarian cancer is characterized as a late-stage.

9. The method of claim 6 , wherein the ovarian cancer is characterized as a late-stage.

10. The method of claim 1 , wherein said antibody is a monoclonal antibody.

11. The method of claim 1 , wherein the antibody is a chimeric antibody.

12. The method of claim 1 , wherein the antibody is a humanized antibody.

13. The method of claim 1 , wherein the antibody is a human antibody.

14. The method of claim 1 , wherein the antigen binding fragment thereof is a FV, a Fab, a Fab′ or a (Fab′) 2 .

15. A method for inhibiting ovarian tumorigenesis, the method comprising a step of contacting ovarian cancer cells with an antibody, or an antigen binding fragment thereof, capable of specifically binding to a polypeptide having a sequence identical to SEQ ID NO.:70.

Assignments (6)
PATENT SECURITY AGREEMENT Recorded Dec 27, 2022
From: ADC THERAPEUTICS SA
To: OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.
Reel/Frame 062228/0763 →
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT Recorded Aug 16, 2022
From: DEERFIELD PARTNERS, L.P.
To: ADC THERAPEUTICS SA
Reel/Frame 061200/0750 →
IP PLEDGE AGREEMENT Recorded Jun 29, 2020
From: ADC THERAPEUTICS SA
To: DEERFIELD PARTNERS, L.P.
Reel/Frame 053080/0309 →
SECURITY INTEREST Recorded May 19, 2020
From: ADC THERAPEUTICS SA
To: DEERFIELD PARTNERS, L.P., AS GRANTEE
Reel/Frame 052696/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2017
From: ALETHIA BIOTHERAPEUTICS INC.
To: ADC THERAPEUTICS SA
Reel/Frame 042880/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2008
From: SOOKNANAN, ROY RABINDRANAUTH; TREMBLAY, GILLES BERNARD; FILION, MARIO
To: ALETHIA BIOTHERAPEUTICS INC.
Reel/Frame 022005/0351 →